Advertisement

The Latest

The U.S. only has slightly better-than-average cancer mortality rates than other high-income countries despite spending twice as much on associated care, a study published May 27 in JAMA Health Forum found.

The FDA expanded its approval for CAR-T therapy in treating cancer patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. 

Advertisement